Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies

Bispecific antibodies have shown significant clinical efficacy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphomas and multiple myeloma, expanding treatment options for these patients. While these advancements are promising, it is important to be aware of associated side effects, such as cytokine release syndrome, neutropenia and infections. Gonugunta et al. provide valuable insights into the infection risks linked to the use of bispecific antibodies in haematological malignancies, drawing on both clinical trial data and real‐world experiences. Commentary on: Gonugunta et al. Risk of infections with bispecific antibodies in B‐cell non‐Hodgkin lymphomas and multiple myeloma—The current state. Br J Haematol 2024; 205:1197‐1201.